RxDoctor Payments Data

Peggy Smith

Family · University Place, WANPI 1467504084

Payments from drug & device makers

$1,054in general payments, 2019–2025

Across 38 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$294
  • Lilly USA, LLC$272
  • Boehringer Ingelheim$123
  • Biohaven Pharmaceutical Holding Company Ltd.$119
  • Novo Nordisk$55
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • plus $147 from 6 others

What the payments were for

  • Food & beverage$1,054100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,054 in reported general payments places this provider in the 80th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$130,668
Medicare patients
281
Services billed
1,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$16,925
RybelsusSemaglutide14$16,144
Lacosamide57$9,818
XareltoRivaroxaban21$9,423
MyrbetriqMirabegron14$7,657
Fentanyl75$7,166
Memantine Hcl100$5,596
Oxycodone Hcl213$5,176
Quetiapine Fumarate177$4,069
Clonidine29$3,692
Potassium Chloride53$2,712
Levothyroxine Sodium163$2,421
Clonazepam101$2,388
Buspirone Hcl119$2,353
Gabapentin117$2,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$55$16,14414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,706 family providers in Washington.

Other family in University Place

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →